This is an open-label, randomized, multi-cohort, multi-center, phase Ib/II study to evaluate the safety and efficacy of Adebrelimab plus Irinotecan Liposome (II) with or without Famitinib in patients with extensive-stage small cell lung cancer (ES-SCLC) pre-treated with immune checkpoint inhibitor(s).
Willing to participate and sign the informed consent form.
Age: 18-75 years old, male or female.
ECOG PS: 0-1 points.
Histologically or cytologically confirmed of extensive stage small cell lung cancer (according to the International Association for the Study of Lung Cancer, 8th Edition or VALG II staging system).
Non-small cell lung cancer or non-small cell lung cancer admixed with components of small cell lung cancer, as confirmed by histology or cytology.
With > 2 lines of prior chemotherapy.
Patients previously treated with topoisomerase I inhibitors.
With primary resistance, defined as patients who do not respond to first-line treatment or progress within 90 days after the end of treatment.
Baohui Han
Lead sponsor
Shanghai Chest Hospital
Sponsor institution